A Multicenter Single-arm Phase II Interventional Study to Evaluate the Activity and Safety of the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib.
Latest Information Update: 25 Apr 2024
At a glance
- Drugs Lorlatinib (Primary) ; Pemetrexed (Primary) ; Carboplatin; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 25 Apr 2024 New trial record